|
| 1 |
Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
Kyunghwan Oh, Hee Seung Hong, Nam Seok Ham, Jungbok Lee, Sang Hyoung Park, Suk-Kyun Yang, Hyuk Yoon, You Sun Kim, Chang Hwan Choi, Byong Duk Ye
Intest Res.2023;21(1):137-147. Published online 2022 July 12
DOI: http://dx.doi.org/10.5217/ir.2021.00173
|
|
| 2 |
The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
Myeong Geun Choi, Byong Duk Ye, Suk-Kyun Yang, Tae Sun Shim, Kyung-Wook Jo, Sang Hyoung Park
|
|
| 3 |
Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)
Tadakazu Hisamatsu, Hyo Jong Kim, Satoshi Motoya, Yasuo Suzuki, Yoshifumi Ohnishi, Noriyuki Fujii, Nobuko Matsushima, Richuan Zheng, Colleen W. Marano
Intest Res.2021;19(4):386-397. Published online 2020 December 1
DOI: http://dx.doi.org/10.5217/ir.2020.00080
|
|
| 4 |
Ustekinumab is effective in biological refractory Crohn’s disease patients–regardless of approval study selection criteria
Sadik Saman, Martin Goetz, Judith Wendler, Nisar P. Malek, Jan Wehkamp, Thomas Klag
Intest Res.2019;17(3):340-348. Published online 2019 May 31
DOI: http://dx.doi.org/10.5217/ir.2019.00012
|
|
| 5 |
Economic Factors as Major Determinants of Ustekinumab Drug Survival of Patients with Chronic Plaque Psoriasis in Korea
Chong Won Choi, Seungkeol Yang, Gwanghyun Jo, Bo Ri Kim, Sang Woong Youn
Ann Dermatol.2018;30(6):668-675. Published online 2018 October 26
DOI: http://dx.doi.org/10.5021/ad.2018.30.6.668
|
|
| 6 |
Emerging Therapies: What Are Promising in the Near Future?
Geom Seog Seo, Sung Hee Lee
|
|
| 7 |
Economic Burden Can Be the Major Determining Factor Resulting in Short-Term Intermittent and Repetitive Ustekinumab Treatment for Moderate-to-Severe Psoriasis
Chong Won Choi, Ji Young Choi, Bo Ri Kim, Sang Woong Youn
Ann Dermatol.2018;30(2):179-185. Published online 2018 February 21
DOI: http://dx.doi.org/10.5021/ad.2018.30.2.179
|
|
| 8 |
Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies
Toshifumi Hibi, Yuya Imai, Yoko Murata, Nobuko Matsushima, Richuan Zheng, Christopher Gasink
Intest Res.2017;15(4):475-486. Published online 2017 October 23
DOI: http://dx.doi.org/10.5217/ir.2017.15.4.475
|
|
| 9 |
The MARCOPOLO Study of Ustekinumab Utilization and Efficacy in a Real-World Setting: Treatment of Patients with Plaque Psoriasis in Asia-Pacific Countries
Sang Woong Youn, Tsen-Fang Tsai, Colin Theng, Siew-Eng Choon, Benny E. Wiryadi, Antonio Pires, Weihao Tan, Min-Geol Lee,
Ann Dermatol.2016;28(2):222-231. Published online 2016 March 31
DOI: http://dx.doi.org/10.5021/ad.2016.28.2.222
|
|
| 10 |
Severe Nail Fold Psoriasis Extending from Nail Psoriasis Resolved with Ustekinumab: Suggestion of a Cytokine Overflow Theory in the Nail Unit
Sang Young Byun, Bo Ri Kim, Jae Woo Choi, Sang Woong Youn
Ann Dermatol.2016;28(1):94-97. Published online 2016 January 28
DOI: http://dx.doi.org/10.5021/ad.2016.28.1.94
|
|
| 11 |
The use of biologics for severe psoriasis
Sang Woong Youn
|
|
| 12 |
Appearance of Psoriasis after Tumor Necrosis Factor-α Blocker and Use of Ustekinumab or Tocilizumab for Refractory Monoarthritis
Jinyoung Moon, Nakwon Kwak, Jin Lim, Dong Jin Go, Jae Hyun Lee, Jin Kyun Park, Eun Bong Lee, Yeong Wook Song, Jai Il Youn, Eun Young Lee
J Rheum Dis.2015;22(4):263-268. Published online 2015 August 25
DOI: http://dx.doi.org/10.4078/jrd.2015.22.4.263
|
|
